Unigene Laboratories Inc., a biopharmaceutical company, was incorporated in the State of Delaware in 1980. Our single business segment focuses on the research, production and drug delivery of small proteins, referred to as peptides, for therapeutic use. We have patented oral and nasal drug delivery technologies that have been shown to deliver therapeutically useful amounts of various peptides into the bloodstream, as well as manufacturing technologies for producing certain natural therapeutic peptides cost-effectively. Collectively, we brand our patented therapeutic peptide drug delivery and manufacturing technologies as “Peptelligence™”. We have three operating locations: administrative and regulatory offices in Boonton, New Jersey; a laboratory research facility in Fairfield, New Jersey; and a pharmaceutical production facility in Boonton, New Jersey.
Company profile
Ticker
UGNE
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
222328609
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
1 Jul 19
8-K
Bankruptcy or Receivership
2 Jul 13
8-K
Entry into a Material Definitive Agreement
17 Jun 13
8-K
Entry into a Material Definitive Agreement
7 Jun 13
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
29 May 13
8-K
Entry into a Material Definitive Agreement
20 May 13
8-K/A
Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update
17 May 13
10-Q
2013 Q1
Quarterly report
14 May 13
8-K
Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update
14 May 13
8-K
Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
13 May 13
Latest ownership filings
SC 13D/A
Unigene Laboratories Inc
13 Jun 13
SC 13D/A
Unigene Laboratories Inc
24 May 13
SC 13D/A
Victory Park Capital Advisors, LLC
3 May 13
SC 13D/A
Victory Park Capital Advisors, LLC
12 Apr 13
SC 13D/A
Victory Park Capital Advisors, LLC
5 Oct 12
SC 13D/A
Victory Park Capital Advisors, LLC
19 Jul 12
SC 13D/A
Victory Park Capital Advisors, LLC
8 Jun 12
SC 13D/A
WYNNEFIELD PARTNERS SMALL CAP VALUE LP
29 May 12
SC 13D/A
Victory Park Capital Advisors, LLC
11 Jul 11
SC 13D/A
Victory Park Capital Advisors, LLC
26 Jan 11
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 29.64 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bradley Foster & Sargent | 29.64 k | $0.00 |